🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,328 results for “Xiyuan Hospital of China Academy of Chinese Medical Sciences” Clear

  1. golidocitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T Cell Lymphoma

    phase 3 small molecule active

    1 trial

  2. internal mammary nodal irradiation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 3 other active

    1 trial

  3. mCapOX plus Cetuximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  4. misoprostol

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Labor Induction

    phase 3 small molecule completed

    1 trial

  5. mitomycin C-based hyperthermic intraperitoneal chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 3 other active

    1 trial

  6. mosapride citrate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Constipation

    phase 3 small molecule completed

    1 trial

  7. neoadjuvant chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  8. novel stent

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Cancer

    phase 3 other active

    1 trial

  9. patients were assigned to receive TNT or iTNT management

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  10. poliovirus vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Poliomyelitis

    phase 3 mab completed

    1 trial

  11. pralatrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Peripheral T-Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  12. preoperative short-course radiotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Neoplasms

    phase 3 other terminated

    1 trial

  13. recombinant human thrombopoietin (rhTPO); dexamethasone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule completed

    1 trial

  14. recombinant human thrombopoietin (rhTPO); rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule terminated

    1 trial

  15. rhTPO in combination with Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule completed

    1 trial

  16. rituximab; recombinant human thrombopoietin (rhTPO)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule completed

    1 trial

  17. shenfu injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Septic Shock

    phase 3 small molecule active

    1 trial

  18. six courses of zanubrutinib, rituximab and lenalidomide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diffuse Large B-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  19. tacrolimus capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lupus Nephritis

    phase 3 small molecule terminated

    1 trial

  20. toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Cancer

    phase 3 small molecule active

    1 trial

  21. urapidil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke, Acute

    phase 3 small molecule completed

    1 trial

  22. 0.2mg group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Opioid Dependence

    phase 2 small molecule active

    1 trial

  23. 16mg，KB

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sepsis

    phase 2 small molecule active

    1 trial

  24. 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tuberculosis

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources